In this section we give you an overview of the latest news and updates regarding the development of DEBx Medical and our product DEBRICHEM. Follow us on LinkedIn for more up-to-date content!
Objective: To estimate whether the topical debriding agent, Debrichem, could potentially afford the UK’s National Health Service (NHS) a cost-effective intervention for the management of
All testing was performed in triplicate and testing was completed twice, separated by 2 weeks apart. This was to ensure reproducibility (Parker et al., 2018).
“If biofilms keep chronic wounds from healing, then Debrichem® is the solution” It is with great pride and anticipation that Debx Africa (Pty) Ltd are
This licence authorises manufacture by the licence holder named; if the business should change hands, the company or person taking over the business will have
The licence holder and the persons described and named in Annexure 1 shall at all times ensure that all medical devices distributed, irrespective of its
Within one minute of topical application of a red gel intends to facilitate the removal of unhealthy tissue. The semi fluid substance containing an acid
The wound had been present for 6 weeks when the patient entered the clinic for DEBRICHEM treatment. The lesion on the right forefoot was severely
After full granulation was referred to another center for skin graft and the list for follow up. The patient entered the clinic with a chronic
